HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
HALOZYME THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.50+0.66 (+0.54%)
Close on Oct 19, 2026
- Market cap
- $14.85B
- P/E (TTM)
- 36.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
124M of 113M shares
Institutional holders
668
107 new, 66 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 90 sales
Net sold $41.20M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Capital Management | 6,173,547 | 5.21% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 12,612,300 | 10.20% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HALO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,271,095 | 11.69% | $1.04B | +6,042 | 0.02% |
| Vanguard Capital Management LLC | 5,351,312 | 4.71% | $418.85M | +80,094 | 0.01% |
| Vanguard Portfolio Management LLC | 5,299,008 | 4.67% | $414.75M | +49,802 | 0.02% |
| State Street Corp | 5,179,434 | 4.56% | $405.38M | +241,580 | 0.01% |
| Invesco Ltd. | 3,177,997 | 2.80% | $248.74M | −834,497 | 0.02% |
| Morgan Stanley | 2,832,594 | 2.50% | $221.71M | +270,285 | 0.01% |
| Boston Partners | 2,773,568 | 2.44% | $216.82M | +89,885 | 0.19% |
| Bank Of America Corp /De/ | 2,740,561 | 2.41% | $214.50M | −172,548 | 0.01% |
| Geode Capital Management, LLC | 2,519,951 | 2.22% | $197.28M | +14,165 | 0.01% |
| William Blair Investment Management, LLC | 2,511,050 | 2.21% | $196.54M | −14,925 | 0.59% |
| Snyder Capital Management L P | 2,396,101 | 2.11% | $187.54M | +73,024 | 3.24% |
| Dimensional Fund Advisors LP | 2,089,567 | 1.84% | $163.54M | +9,740 | 0.03% |
| D. E. Shaw & Co., Inc. | 2,006,479 | 1.77% | $157.05M | +137,771 | 0.07% |
| Assenagon Asset Management S.A. | 1,995,286 | 1.76% | $156.17M | +1,973,964 | 0.10% |
| Los Angeles Capital Management LLC | 1,938,035 | 1.71% | $151.69M | +1,248,120 | 0.56% |
| Royal London Asset Management Ltd | 1,810,815 | 1.60% | $141.73M | +200,262 | 0.26% |
| Arrowstreet Capital, Limited Partnership | 1,704,623 | 1.50% | $133.42M | −213,526 | 0.06% |
| Alliancebernstein L.P. | 1,696,538 | 1.49% | $109.65M | −39,963 | 0.04% |
| Two Sigma Investments, LP | 1,653,285 | 1.46% | $129.40M | +68,324 | 0.09% |
| UBS Group AG | 1,492,224 | 1.31% | $116.80M | +578,221 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 668 | 124M | 100.0% | 107 / 270 | 205 / 66 | 16M | 11M |
| Q1 2026 | 636 | 120M | 100.0% | 98 / 234 | 215 / 70 | 24M | 16M |
| Q4 2025 | 618 | 125M | 100.0% | 109 / 216 | 224 / 82 | 20M | 15M |
| Q3 2025 | 603 | 120M | 100.0% | 112 / 187 | 238 / 52 | 17M | 14M |
| Q2 2025 | 551 | 117M | 100.0% | 90 / 181 | 214 / 80 | 17M | 21M |
| Q1 2025 | 549 | 121M | 100.0% | 97 / 216 | 170 / 49 | 12M | 11M |
| Q4 2024 | 508 | 123M | 100.0% | 90 / 180 | 177 / 82 | 13M | 18M |
| Q3 2024 | 509 | 128M | 100.0% | 94 / 179 | 168 / 41 | 31M | 11M |
| Q2 2024 | 460 | 125M | 100.0% | 79 / 161 | 160 / 30 | 8M | 12M |
| Q1 2024 | 413 | 130M | 100.0% | 57 / 163 | 140 / 52 | 12M | 11M |
| Q4 2023 | 410 | 129M | 100.0% | 63 / 146 | 146 / 36 | 15M | 9M |
| Q3 2023 | 389 | 123M | 100.0% | 51 / 136 | 144 / 30 | 9M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of HALO | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 4,059,222 | 3.58% | $317.72M | 0.26% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,762,787 | 3.32% | $294.51M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,721,119 | 2.40% | $212.98M | 0.11% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,566,912 | 1.38% | $122.64M | 0.26% | Jun 30, 2026 |
| Disciplined Value Mid Cap Fund | 1,430,565 | 1.26% | $111.97M | 0.48% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,412,358 | 1.24% | $110.55M | 1.03% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,359,907 | 1.20% | $106.44M | 0.11% | Jun 30, 2026 |
| Invesco Discovery Fund | 1,254,102 | 1.10% | $83.45M | 1.07% | May 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,119,086 | 0.99% | $87.59M | 3.11% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 968,755 | 0.85% | $75.82M | 1.23% | Jun 30, 2026 |
| Vanguard Explorer Fund | 832,286 | 0.73% | $68.70M | 0.31% | Jul 31, 2026 |
| iShares Biotechnology ETF | 831,875 | 0.73% | $65.11M | 0.72% | Jun 30, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 709,843 | 0.63% | $55.56M | 0.49% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 693,863 | 0.61% | $54.31M | 0.25% | Jun 30, 2026 |
| Putnam Small Cap Growth Fund | 617,928 | 0.54% | $48.37M | 1.42% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Helen Torley | PRESIDENT AND CEO, Director | 787,780 | 0.69% | Sep 11, 2026 |
| Darren Snellgrove | SVP, Chief Financial Officer | – | – | Jul 2, 2026 |
| David A. Ramsay | EVP, PRESIDENT, DRUG DELIVERY | 10,000 | 0.01% | Jul 2, 2026 |
| Mark Howard Snyder | SVP, CHIEF LEGAL OFFICER | 52,644 | 0.05% | Jun 15, 2026 |
| Cortney Caudill | SVP, CHIEF OPERATING OFFICER | 15,912 | 0.01% | Mar 10, 2026 |
| Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | 42,102 | 0.04% | Feb 24, 2026 |
| Michael J. LaBarre | SVP, CHIEF TECHNICAL OFFICER | 173,756 | 0.15% | Feb 27, 2025 |
| Matthew L. Posard | Director | 58,839 | 0.05% | Sep 17, 2026 |
| Dannielle Appelhans | Director | 1,161 | 0.00% | Sep 2, 2026 |
| Bernadette Connaughton | Director | 40,418 | 0.04% | Aug 11, 2026 |
| Mahesh Krishnan | Director | 14,462 | 0.01% | Jun 30, 2026 |
| Jeffrey William Henderson | Director | 36,572 | 0.03% | May 7, 2026 |
| Barbara Gayle Duncan | Director | 23,715 | 0.02% | May 7, 2026 |
| James Paul Lang | Director | 4,685 | 0.00% | May 7, 2026 |
| Akiko Moni Miyashita | Director | 24,937 | 0.02% | May 2, 2025 |
| Connie Matsui | Director | 183,035 | 0.16% | Dec 3, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Matthew L. Posard Director | Sep 16, 2026 | Sale(10b5-1 plan) | −4,000 | $108.99 | $435.96K | 58,839 |
| Matthew L. Posard Director | Sep 16, 2026 | Sale(10b5-1 plan) | −3,100 | $106.13 | $329.00K | 74,735 |
| Matthew L. Posard Director | Sep 16, 2026 | Sale(10b5-1 plan) | −8,896 | $108.04 | $961.12K | 62,839 |
| Matthew L. Posard Director | Sep 16, 2026 | Sale(10b5-1 plan) | −3,000 | $106.83 | $320.49K | 71,735 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 11, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −15,492 | $107.15 | $1.66M | 772,288 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −4,508 | $107.55 | $484.84K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −5,412 | $107.58 | $582.22K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −14,588 | $107.01 | $1.56M | 773,192 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 10, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −13,304 | $107.22 | $1.43M | 774,476 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 9, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −6,596 | $107.82 | $711.18K | 767,880 |
| Helen Torley PRESIDENT AND CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −100 | $108.67 | $10.87K | 767,780 |
| Dannielle Appelhans Director | Sep 1, 2026 | Award | +1,161 | – | – | 1,161 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −3,200 | $107.77 | $344.86K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −9,600 | $107.22 | $1.03M | 770,980 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −7,200 | $106.36 | $765.79K | 780,580 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 19, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −9,400 | $104.87 | $985.78K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −4,897 | $104.11 | $509.83K | 777,180 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −5,703 | $103.08 | $587.87K | 782,077 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 18, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −900 | $98.96 | $89.06K | 786,880 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Option exercise | +20,000 | $18.41 | $368.20K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −500 | $100.46 | $50.23K | 786,380 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −2,100 | $101.77 | $213.72K | 784,280 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −9,000 | $102.55 | $922.95K | 775,280 |
| Helen Torley PRESIDENT AND CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −7,500 | $103.48 | $776.10K | 767,780 |
| Bernadette Connaughton Director | Aug 10, 2026 | Sale(10b5-1 plan) | −1,626 | $102.80 | $167.15K | 40,418 |
| Helen Torley PRESIDENT AND CEO, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −1,035 | $80.19 | $83.00K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −888 | $79.28 | $70.40K | 768,815 |
| Helen Torley PRESIDENT AND CEO, Director | Jul 8, 2026 | Option exercise | +1,923 | $12.07 | $23.21K | 769,703 |
| Bernadette Connaughton Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,000 | $76.40 | $76.40K | 42,669 |
| Bernadette Connaughton Director | Jul 1, 2026 | Sale(10b5-1 plan) | −625 | $77.21 | $48.26K | 42,044 |
| David A. Ramsay EVP, PRESIDENT, DRUG DELIVERY | Jun 30, 2026 | Option exercise | +10,000 | – | – | 10,000 |
| David A. Ramsay EVP, PRESIDENT, DRUG DELIVERY | Jun 30, 2026 | Tax withholding | −5,408 | $78.27 | $423.28K | 4,592 |
| Mahesh Krishnan Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,304 | $75.00 | $547.80K | 14,462 |
| Mahesh Krishnan Director | Jun 29, 2026 | Option exercise | +7,304 | $38.46 | $280.91K | 21,766 |
| Mark Howard Snyder SVP, CHIEF LEGAL OFFICER | Jun 12, 2026 | Option exercise | +5,034 | – | – | 52,644 |
| Mark Howard Snyder SVP, CHIEF LEGAL OFFICER | Jun 12, 2026 | Tax withholding | −2,715 | $69.50 | $188.69K | 49,929 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 3, 2026 | Sale(10b5-1 plan) | −2,000 | $68.74 | $137.48K | 773,880 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 3, 2026 | Sale(10b5-1 plan) | −1,500 | $67.68 | $101.52K | 775,880 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 3, 2026 | Sale(10b5-1 plan) | −400 | $66.37 | $26.55K | 777,380 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 3, 2026 | Option exercise | +10,000 | $12.07 | $120.70K | 777,780 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 3, 2026 | Sale(10b5-1 plan) | −6,100 | $69.69 | $425.11K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 2, 2026 | Sale(10b5-1 plan) | −16,600 | $66.31 | $1.10M | 771,180 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 2, 2026 | Option exercise | +20,000 | $12.07 | $241.40K | 787,780 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 2, 2026 | Sale(10b5-1 plan) | −3,400 | $66.75 | $226.95K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −5,401 | $68.35 | $369.16K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −12,989 | $67.41 | $875.59K | 773,181 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,610 | $66.39 | $106.89K | 786,170 |
| Helen Torley PRESIDENT AND CEO, Director | Jun 1, 2026 | Option exercise | +20,000 | $12.07 | $241.40K | 787,780 |
| Bernadette Connaughton Director | Jun 1, 2026 | Sale(10b5-1 plan) | −1,625 | $66.21 | $107.59K | 43,669 |
| Helen Torley PRESIDENT AND CEO, Director | May 13, 2026 | Option exercise | +10,000 | $12.07 | $120.70K | 777,780 |
| Helen Torley PRESIDENT AND CEO, Director | May 13, 2026 | Sale(10b5-1 plan) | −600 | $70.81 | $42.49K | 767,780 |
| Helen Torley PRESIDENT AND CEO, Director | May 13, 2026 | Sale(10b5-1 plan) | −3,950 | $69.79 | $275.67K | 768,380 |
| Helen Torley PRESIDENT AND CEO, Director | May 13, 2026 | Sale(10b5-1 plan) | −3,350 | $68.88 | $230.75K | 772,330 |
| Helen Torley PRESIDENT AND CEO, Director | May 13, 2026 | Sale(10b5-1 plan) | −2,100 | $68.10 | $143.01K | 775,680 |
| Helen Torley PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −5,900 | $72.15 | $425.69K | 770,580 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Posard Matthew Director | Sep 16, 2026 | 34,226 | $3.64M | Sep 16, 2026 | Restricted Stock Units |
| Torley Helen President, CEO, Director | Aug 17, 2026 | 240,000 | $23.68M | Aug 17, 2026 | Stock Option Exercise |
| A. Caudill Cortney Officer | Aug 11, 2026 | 41,702 | $4.30M | Aug 11, 2026 | Stock Option Exercise |
| Connaughton Bernadette Director | Aug 10, 2026 | 1,626 | $167.67K | Aug 10, 2026 | Restricted Stock Units |
| Krishnan Mahesh Director | Jun 29, 2026 | 7,304 | $547.51K | Jun 29, 2026 | Exercise of Stock Options |
| Labrosse Nicole Former Officer | May 15, 2026 | 14,700 | $986.59K | May 15, 2026 | Restricted stock vesting under a registered plan |
| Torley Helen President, CEO, Director | May 11, 2026 | 101,923 | $6.54M | May 11, 2026 | Stock Option Exercise |
| Connaughton Bernadette Director | May 1, 2026 | 4,875 | $310.34K | May 1, 2026 | Restricted Stock Units |
| A. Caudill Cortney Officer | Mar 10, 2026 | 8,857 | $599.09K | Mar 10, 2026 | Restricted stock vesting under a registered plan |
| A. Caudill Cortney Officer | Mar 9, 2026 | 20,000 | $1.36M | Mar 9, 2026 | Exercise of options under a registered plan |
| Torley Helen President, CEO, Director | Feb 3, 2026 | 150,000 | $11.17M | Feb 3, 2026 | Stock Option Exercise |
| Connaughton Bernadette Director | Jan 5, 2026 | 2,000 | $140.62K | Jan 5, 2026 | Restricted Stock Units |
| Torley Helen President, CEO, Director | Oct 1, 2025 | 136,569 | $10.02M | Oct 1, 2025 | Stock Option Exercise |
| Labrosse Nicole Officer | Sep 10, 2025 | 22,227 | $1.69M | Sep 10, 2025 | Exercise of Stock Options |
| Connaughton Bernadette Director | Sep 2, 2025 | 8,829 | $645.84K | Sep 2, 2025 | Restricted Stock Units |